REMPEX Pharmaceuticals

OLGA LOMOVSKAYA  – antibiotic discovery and development

Dr. Lomovskaya has over 30 years’ experience in discovery and development of antibiotics. The main focus of her academic and industrial research was the studies of antibiotic resistant mechanisms and developing approaches to overcome this resistance. Dr. Lomovskaya’s team at Rempex discovered the first class of efflux pump inhibitors. She led further development of these inhibitors into pre-clinical trials.

BASILEA Pharmaceutic

JURG DREIER – antibiotic discovery and development.

Recently, Dr. Dreier’s team discovered and characterized a novel class of efflux pump inhibitors. He also led several other projects focused on potentiators of antibiotics. The group has expertise and experience in biochemistry, molecular biology and microbiology. Support for various projects is provided in form of cloning, expression and purification of bacterial and human enzymes, development of in vitro assays, kinetic analysis of enzyme inhibition, mode-of-action studies, high-throughput screening, biochemical and biophysical investigations, whole cell assays with bacterial and human cells, and biophysical binding studies.


BRADLEY S. SHERBORNE – chemistry modeling and informatics

Merck is a fully integrated discovery and development pharmaceutical company with extensive expertise in high throughput screening, in vitro biochemical, biophysical, and cell-based pharmacology, medicinal chemistry, cheminformatics, bioinformatics, structural biology, pharmacokinetics, pharmacodynamics and drug metabolism, and in vivo animal models.

Dr. Sherborne’s group contributes computational and cheminformatics support spanning drug target and experimental data analysis through to mechanistic, structure-based and machine learning modeling in compound optimization and drug development.